AME Case Series Checklist –Adapted from CARE Checklist and PROCESS Checklist

Section	Item	Checklist description	Reported on Page Number/Line Number	Reported on Section/Paragraph
Title	1	The diagnosis or intervention of primary focus followed by the words “case series”.	Page 1/Line 3-4	Title/Paragraph 1
Key Words	2	2 to 5 key words that identify diagnoses or interventions in this case series, including "case report" or "case series".	Page 2/Line 47-48	Key words/Paragraph 2
Abstract (no references)	3a	Introduction—What is unique about this case series and what does it add to the scientific literature?	Page 2/Line 40-44	Abstract/Paragraph 1
	3b	Methods—describe what was done, how and when was it done and by whom.	Page 2/Line 35-37	Abstract/Paragraph 1
	3c	Results—what was found.	Page 2/Line 37-39	Abstract/Paragraph 1
	3d	Conclusion—What is the main take-away lesson(s)? What have we learned and what does it mean?	Page 2/Line 40-44	Abstract/Paragraph 1
Introduction	4	Explain the scientific background and rationale for the case series. What is the unifying theme - common disease, exposure, intervention and outcome, etc. Why is this study needed?	Page 2/Line 55-59,67-70	Introduction/Paragrapg 1
Methods	5a	Registration and ethics— 5a.1 State the research registry number in accordance with the declaration of Helsinki - “Every research study involving human subjects must be registered in a publicly accessible database” (this can be obtained from; ResearchRegistry.com or ClinicalTrials.gov or ISRCTN). 5a.2 State whether ethical approval was passed. 5a.3 Provide the patient consent form too.	Page 4/Line 111-114	Methods/Paragrapg 3
	5b	Study design—state the study is a case series and whether prospective or retrospective in design, whether single or multi-center and whether cases are consecutive or non-consecutive.	Page 3/Line 77-79	Methods/Paragrapg 1
	5c	Setting - describe the setting(s)and nature of the institution in which the patient was managed; academic, community or private practice setting? Location(s), and relevant dates, including periods of recruitment, exposure, follow-up, and data collection.	Page 1/Line 8-9	Title/Paragraph 3
	5d	Participants— 5d.1 Describe the relevant characteristics of the participants (history, comorbidities, tumor staging, smoking, etc.). 5d.2 State any eligibility (inclusion/exclusion) criteria and the sources and methods of selection of participants.	Page 3/Line 77-88	Methods/Paragrapg 1

	5e	Intervention—types of intervention (such as pharmacologic, surgical, preventive, self-care) deployed and reasoning behind treatment offered. Pharmacological therapies should include formulation, dosage, strength, route and duration.	Page 3-4/Line 105-110	Methods/Paragrapg 2
	5f	Follow up—describe length and methods of follow-up.	Page 4/Line 130-131	Results/Paragrapg 2
Results	6a	Participants—reports numbers involved and their characteristics (comorbidities, tumor staging, smoking, etc.).	Page 4/Line 118-119	Results/Paragrapg 1
	6b	Any changes in the interventions during the course of the case series (how has it evolved, been tinkered with, what learning occurred, etc.) together with rationale and a diagram if appropriate.	Page 4/Line 126-130	Results/Paragrapg 2
	6c	Outcomes and follow-up—Clinician assessed and patient-reported outcomes (when appropriate) should be stated with inclusion of the time periods at which assessed. Relevant photographs/radiological images should be provided. e.g. 12-month follow-up.	Page 4/Line 130-131	Results/Paragrapg 2 Figures (1-4)
	6d	Where relevant—intervention adherence/compliance and tolerability (how was this assessed). Describe loss to follow-up (express as a percentage) and any explanations for it.	Page 4/Line 126-131	Results/Paragrapg 2
	6e	Complications and adverse or unanticipated events.	Page 5/Line 164-165	Discussion/Paragrapg 3
Discussion	7a	Summarize key results.	Page 8/Line 240-244	Discussion/Paragrapg 6
	7b	Discussion of the relevant literature, implications for clinical practice guidelines. How do outcomes compare with established therapies and the prevailing gold standard? Generate a hypothesis if possible.	Page 7-8/Line 221-240	Discussion/Paragraph 6
	7c	Strengths and limitations of the study.	Page 7-8/Line 235-240	Discussion/Paragraph 6
	7d	The rationale for any conclusions.	Page 6/Line 197-204	Discussion/Paragraph 5
Conclusion	8a	State the key conclusions from the study.	Page 2/Line 40-44	Abstract/Paragraph 1
	8b	State what needs to be done next, further research with what study design.	Page 8/Line 240-245	Discussion/Paragraph 6

Article Information: http://dx.doi.org/10.21037/apm-21-263
*As the checklist was provided upon initial submission, the page number/line number reported may be changed due to copyediting and may not be referable in the published version. In this case, the section/paragraph may be used as an alternative reference.

Materials Design Analysis Reporting (MDAR) Checklist for Authors

The MDAR framework establishes a minimum set of requirements in transparent reporting applicable to studies in the life sciences (see Statement of Task: doi:10.31222/osf.io/9sm4x.). The MDAR checklist is a tool for authors, editors and others seeking to adopt the MDAR framework for transparent reporting in manuscripts and other outputs. Please refer to the MDAR Elaboration Document for additional context for the MDAR framework.

Materials

Antibodies	Yes (indicate where provided:	n/a
For commercial reagents, provide supplier name, catalogue number and RRID, if available.	Page 3/Line 96-102, Methods/Paragraph 2	

Cell materials	Yes (indicate where provided:	n/a
Cell lines: Provide species information, strain. Provide accession number in repository **OR** supplier name, catalog number, clone number, **OR** RRID		No cell materials invovled in the research
Primary cultures: Provide species, strain, sex of origin, genetic modification status.		No cell materials invovled in the research

Experimental animals	Yes (indicate where provided:	n/a
Laboratory animals: Provide species, strain, sex, age, genetic modification status. Provide accession number in repository **OR** supplier name, catalog number, clone number, **OR** RRID		No animals invovled in the research
Animal observed in or captured from the field: Provide species, sex and age where possible		No animals invovled in the research
Model organisms: Provide Accession number in repository (where relevant) **OR** RRID		No animals invovled in the research

Plants and microbes	Yes (indicate where provided:	n/a
Plants: provide species and strain, unique accession number if available, and source (including location for collected wild specimens)		No plants and microbes invovled in the research
Microbes: provide species and strain, unique accession number if available, and source		No animals invovled in the research

Human research participants	Yes (indicate where provided:	n/a
Identify authority granting ethics approval (IRB or equivalent committee(s), provide reference number for approval.	Page 4/Line 111-114, Methods/Paragraph 3	
Provide statement confirming informed consent obtained from study participants.	See informed consent	
Report on age and sex for all study participants.	Page 3/Line 77-80, Methods/Paragraph 1	

Design

Study protocol	Yes (indicate where provided:	n/a
For clinical trials, provide the trial registration number **OR** cite DOI in manuscript.	Page 4/Line 113, Methods/Paragraph 3	

Laboratory protocol	Yes (indicate where provided: section/paragraph)	n/a
Provide DOI or other citation details if detailed step-		No laboratory project

Experimental study design (statistics details)	Yes (indicate where provided:	n/a
State whether and how the following have been done**, or** if they were not carried out.		
Sample size determination		Not carried out
Randomisation		Not carried out
Blinding		Not carried out
Inclusion/exclusion criteria	Page 3/Line 77-80, Methods/Paragraph 1	

Sample definition and in-laboratory replication	Yes (indicate where provided:	n/a
State number of times the experiment was replicated in laboratory		No laboratory project
Define whether data describe technical or biological replicates		No laboratory project

Ethics	Yes (indicate where provided:	n/a
Studies involving human participants: State details of authority granting ethics approval (IRB or equivalent committee(s), provide reference number for approval.	Page 4/Line 111-114, Methods/Paragraph 3	
Studies involving experimental animals: State details of authority granting ethics approval (IRB or equivalent committee(s), provide reference number for approval.		No animals invovled in the research
Studies involving specimen and field samples: State if relevant permits obtained, provide details of authority approving study; if none were required, explain why.		No specimen and field samples invovled in the research

Dual Use Research of Concern (DURC)	Yes (indicate where provided:	n/a
If study is subject to dual use research of concern, state the authority granting approval and reference number for the regulatory approval		It's not dual use research

Analysis

Attrition	Yes (indicate where provided:	n/a
State if sample or data point from the analysis is excluded, and whether the criteria for exclusion were determined and specified in advance.		No deed to decide exclusion criteria

Statistics	Yes (indicate where provided:	n/a
Describe statistical tests used and justify choice of tests.	retrospective analysis，it's suitable for rare diseases	

Data Availability	Yes (indicate where provided:	n/a
State whether newly created datasets are available, including protocols for access or restriction on access.		All the data is stored in our hospital database
If data are publicly available, provide accession number in repository or DOI or URL.		All the data is stored in our hospital database
If publicly available data are reused, provide accession number in repository or DOI or URL, where possible.		All the data is stored in our hospital database

Code Availability	Yes (indicate where provided:	n/a
For all newly generated code and software essential for replicating the main findings of the study:		
State whether the code or software is available.		No code or software in our research
If code is publicly available, provide accession number in repository, or DOI or URL.		No code or software in our research

Reporting

Adherence to community standards	Yes (indicate where provided: section/paragraph)	n/a
MDAR framework recommends adoption of discipline-specific guidelines, established and endorsed through community initiatives. Journals have their own policy about requiring specific guidelines and recommendations to complement MDAR.		
State if relevant guidelines (eg., ICMJE, MIBBI, ARRIVE) have been followed, and whether a checklist (eg., CONSORT, PRISMA, ARRIVE) is provided with the manuscript.	ICMJE guidelines were followed, as the journal follows ICMJE recommendations for publication.	

Article Information: http://dx.doi.org/10.21037/apm-21-263